Biogen Idec, Inc. (BIIB) Misses Q4 EPS by 6c; Guides FY13 EPS Below Views
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q4 EPS of $1.40, $0.06 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.38 billion.
Sees FY2013 EPS of $7.15 - $7.25, versus the consensus of $7.27. Sees revs up about 10 percent.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Sees FY2013 EPS of $7.15 - $7.25, versus the consensus of $7.27. Sees revs up about 10 percent.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.